APGE vs. ACLX, IMCR, SWTX, IOVA, CGON, IBRX, DNLI, KYMR, VCEL, and DNA
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Arcellx (ACLX), Immunocore (IMCR), SpringWorks Therapeutics (SWTX), Iovance Biotherapeutics (IOVA), CG Oncology (CGON), ImmunityBio (IBRX), Denali Therapeutics (DNLI), Kymera Therapeutics (KYMR), Vericel (VCEL), and Ginkgo Bioworks (DNA). These companies are all part of the "biological products, except diagnostic" industry.
Arcellx (NASDAQ:ACLX) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking.
Arcellx has higher revenue and earnings than Apogee Therapeutics.
Apogee Therapeutics has a net margin of 0.00% compared to Apogee Therapeutics' net margin of -64.08%. Arcellx's return on equity of 0.00% beat Apogee Therapeutics' return on equity.
Arcellx received 27 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 74.55% of users gave Arcellx an outperform vote.
96.0% of Arcellx shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 6.2% of Arcellx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Arcellx presently has a consensus target price of $75.64, indicating a potential upside of 45.68%. Apogee Therapeutics has a consensus target price of $71.83, indicating a potential upside of 52.42%. Given Arcellx's higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Arcellx.
In the previous week, Arcellx had 2 more articles in the media than Apogee Therapeutics. MarketBeat recorded 4 mentions for Arcellx and 2 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 0.53 beat Arcellx's score of 0.00 indicating that Arcellx is being referred to more favorably in the media.
Summary
Arcellx beats Apogee Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
